Bibliographic Details
| Title: |
SERUM SPHINGOLIPIDS AS CANDIDATE BIOMARKERS IN RHEUMATOID ARTHRITIS. |
| Authors: |
Cruz-Machado, Ana Rita, G., Miltenyi, Conceição, Vasco A., Calado, Ângelo, I. P., Lopes, Fuller, Maria, Fonseca, J. E. |
| Source: |
Acta Reumatológica Portuguesa; 2019 Special Issue, p63-64, 2p |
| Abstract: |
Background: The identification of rheumatoid arthritis (RA) serum biomarkers with applicability to early diagnosis and treatment stratification is a relevant unmet medical need. Various lipid species, including sphingolipids, which are implicated in inflammatory pathways, were identified to be significantly increased in the synovial fluid (SF) of RA patients and have been shown to be associated with inflammatory activity in other diseases. Objectives: To identify serum sphingolipids as candidate serum biomarkers in RA. Methods: We performed lipidomics analyses on Ceramide (Cer), Monohexosylceramide (MHCer) and Sphingosine (So) using high-performance liquid chromatography-mass spectrometry in the serum of 19 established RA, 18 early arthritis patients who latter developed classification criteria for RA, 17 early arthritis patients who did not develop classification criteria for RA, 12 established spondyloarthritis (SpA) patients and 20 age and gender matched healthy controls. We carried out multiple regression analyses considering age at diagnosis, gender, DAS-28, medication and disease duration as independent variables to compare patient groups with controls. Results: Patients with established RA had increased levels of Cer, MHCer and So vs. controls, when including age and gender in the analyses. MHCer was also increased when additionally controlling for medication (conventional disease-modifying anti-rheumatic drugs and corticoid treatment). On the contrary, SpA patients, who were all on nonsteroidal anti-inflammatory drugs, had significantly decreased levels of Cer, compared to controls, in both analyses. Conclusions: Our results suggest that there is an increase in certain sphingolipid levels in the serum of RA patients, in line with previous observations on SF. This suggests that sphingolipids play a role in the pathophysiology of RA and should be further explored as serum biomarkers in RA. [ABSTRACT FROM AUTHOR] |
|
Copyright of Acta Reumatológica Portuguesa is the property of Sociedade Portuguesa de Reumatologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Supplemental Index |
